CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
28. März 2024 15:22 ET
|
AVEO Pharmaceuticals, Inc.
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned...
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
25. März 2024 08:10 ET
|
AVEO Pharmaceuticals, Inc.
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from...
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
06. Februar 2024 08:10 ET
|
AVEO Pharmaceuticals, Inc.
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib